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Background: The increasing incidence and prevalence of atopic dermatitis (AD) demands new thera-
peutic approaches for treating the disease. We investigated the therapeutic efﬁcacy of immunomodulator
FTY720 ointment (ﬁngolimod) for mite-induced intractable AD using an NC/Nga mouse model.
Methods: Female NC/Nga mice that developed severe AD were divided into four groups: (1) FTY720
(0.001% FTY720 ointment), (2) tacrolimus (tacrolimus hydrate ointment) (3) betamethasone (betame-
thasone ointment), and (4) ointment base (hydrophilic petrolatum), all of which received treatment six
times per week. Therapeutic efﬁcacy after two weeks was evaluated in terms of AD severity, histo-
chemical observations (epidermal hypertrophy, mast cell accumulation, and CD3þ T cell inﬁltration),
transepidermal water loss (TEWL), and epidermal barrier function (ﬁlaggrin expression).
Results: Betamethasone treatment showed little effect, conﬁrming that the AD was intractable. In the
FTY720 group, AD improved signiﬁcantly compared with the ointment base group, as did epidermal
hypertrophy, mast cell accumulation, and CD3þ T cell inﬁltration. In contrast, AD in the tacrolimus and
betamethasone groups did not improve signiﬁcantly, nor did epidermal hypertrophy or mast cell
accumulation. Furthermore, in the FTY720 group, TEWL decreased signiﬁcantly compared with the
ointment base group, and ﬁlaggrin expression signiﬁcantly increased compared with the betamethasone
and ointment base groups.
Conclusions: FTY720 ointment is a promising candidate for treatment of intractable AD. These ﬁndings
also provide the ﬁrst evidence that FTY720 ointment ameliorates epidermal barrier function.
Copyright © 2015, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Atopic dermatitis (AD) is the most common skin disease and can
signiﬁcantly compromise quality of life due to sleep disruption,
social awkwardness, and emotional distress. Most infants who
present with mild AD will outgrow their skin disease in later
childhood.1 Recent studies have indicated that defects in epidermal
barrier function (tight junction [TJ] and stratum corneum [SC]
barriers) contribute greatly to triggering and perpetuating skin
inﬂammation associated with AD. With AD, the skin is character-




rgology. Production and hosting by Elseceramides and ﬁlaggrin.1 Claudin-1 and ﬁlaggrin play a critical role
in TJ and SC barrier formation, respectively. In AD, therapeutic
targets include not only the inﬂammatory response but also dry
skin associated with epidermal barrier dysfunction.
The novel immunomodulator FTY720 (ﬁngolimod) was syn-
thesized by structural modiﬁcation of myriocin (ISP-I), a compound
from Isaria sinclairii.2,3 FTY720 was discovered by Tetsuro Fujita (F)
in collaboration with Taito Co., Ltd. (T; Mitsui Sugar, Tokyo, Japan)
and Yoshitomi Pharmaceutical Industries, Ltd. (Y; Mitsubishi
Tanabe Pharma Corporation, Osaka, Japan) in Japan. As a result of
structural modiﬁcation studies of ISP-I, the reduction of toxicity and
the enhancement of immunosuppressive activity were acquired.
FTY720 has been reported to be effective not only in preclinical
transplantation models, but also in preventing development of
various immunologic diseases in animal models, including rheu-
matoid arthritis,4 myasthenia gravis,5 multiple sclerosis,6 type 1vier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
T. Tsuji et al. / Allergology International 65 (2016) 172e179 173diabetes mellitus,7,8 and AD.9e11 FTY720 was approved for treat-
ment of human multiple sclerosis in the Russia in 2010. Thereafter,
it has been approved for use in at least 50 countries (United States,
European Union, Japan, etc.).
The mechanism of action of FTY720 differs from that of estab-
lished immunosuppressants, such as tacrolimus hydrate and
cyclosporine. In vivo, FTY720 is rapidly phosphorylated by sphin-
gosine kinase 2 to phospho-FTY720d the active form of the drug.
Phospho-FTY720 is an agonist of sphingosine 1-phosphate receptor
[S1PR]. Interestingly, phospho-FTY720 is able to bind to four S1PRs
(S1P1, S1P3, S1P4, and S1P5), rendering it a potentially useful agonist
of S1PR. This signaling induces internalization and intracellular
partial degradation of the receptor.12e14 As a result, FTY720 sup-
presses the immune response by sequestering circulating mature
lymphocytes from the blood and peripheral tissue to the secondary
lymphoid tissue and thymus.15,16 In contrast, S1P2 binds S1P but not
phospho-FTY720. At oral therapeutic doses, FTY720 does not affect
T cell and B cell responses in vitro or in vivo.9,17 Because FTY720
treatment allows for preservation of many aspects of immune
function, including the total number of lymphocytes, capacity for
lymphocyte activation in the lymph nodes and tissue, capacity for
generating antibodies, and innate immune response,18,19 there is
only a limited increase in susceptibility to infectious disease, such
as herpes virus infection and urinary tract infection.20 Furthermore,
immune memory function is not impaired.17
NC/Nga mice have been used as a murine model of human AD.21
In conventional circumstances, the human AD-like skin lesions
spontaneously appear with hyper-immunoglobulin E (IgE) pro-
duction, while in a speciﬁc pathogen-free environment, mice show
neither AD nor hyper-IgE production.21 We previously reportedFig. 1. Therapeutic effects of each treatment on atopic dermatitis in NC/Nga mice. Female NC
FTY720 ointment, 100 mg/affected area, n ¼ 8, C), (2) tacrolimus (tacrolimus hydrate oint
100 mg/affected area, n ¼ 8,,), or (4) ointment base (hydrophilic petrolatum, 100 mg/affect
with small horizontal bars indicates the standard deviation. The signiﬁcance of the differenc
FTY720 group vs. betamethasone group), **(the FTY720 group vs. the ointment base group)
ointment base group) denotes P < 0.05. (b) Representative pictures, illustrating different skthat oral FTY720 in combination with betamethasone ointment
signiﬁcantly improved spontaneous10 and mite-induced11 AD in an
NC/Nga mouse model.
In the present study, we examined the local efﬁcacy of FTY720
ointment for treating established steroid-resistant (intractable) AD
using an NC/Nga mouse model.
Methods
Animals and ethics
Nine-week-old female NC/Nga mice bred under speciﬁc
pathogen-free (SPF) conditions were purchased from Japan SLC Inc.,
Shizuoka, Japan. The mice were bred and maintained under SPF
conditions (23 ± 1 C and 47e67% humidity, under a 12 h light/dark
cycle), and given g-ray-irradiated food (RCF-1; Orientalbio Co., Ltd.,
Kyoto, Japan) and distilled water ad libitum. This study was per-
formed according to a protocol approved by the Institutional Ani-
mal Care Committee of Setsunan University (Nos. 12-11-16-02-S-
239 and 12-12-16-02-S-278). Throughout the experimental pro-
cedures, every effort was made to minimize animal suffering and
the number of animals used.
Drugs
2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydro-
chloride (FTY720, ﬁngolimod) was kindly provided by Yoshitomi
Pharmaceutical Industries, Ltd., Japan. 0.001% FTY720 ointment
was prepared by mixing 0.5 mL of 0.1 mg/mL FTY720 with 4.5 g of
hydrophilic petrolatum. Betamethasone valerate ointment (0.12%/Nga mice with severe skin lesions were treated for two weeks with (1) FTY720 (0.001%
ment, 100 mg/affected area, n ¼ 8, >), (3) betamethasone (betamethasone ointment,
ed area, n ¼ 8,△) six times per week. (a) Each value is the mean, while the vertical bar
e in atopic dermatitis (AD) score was examined using the ManneWhitney U test. *(the
, y(the tacrolimus group vs. betamethasone group), and z(the tacrolimus group vs. the
in symptoms at the end of the observation period in each group.
Fig. 2. Serum immunoglobulin E concentration. Female NC/Nga mice with severe skin
lesions were treated for two weeks with (1) FTY720 (0.001% FTY720 ointment, 100 mg/
affected area, n ¼ 8,C), (2) tacrolimus (tacrolimus hydrate ointment, 100 mg/affected
area, n ¼ 8, >), (3) betamethasone (betamethasone ointment, 100 mg/affected area,
n ¼ 8,,), or (4) ointment base (hydrophilic petrolatum, 100 mg/affected area, n ¼ 8,
△) six times per week. Serum immunoglobulin E (IgE) concentration was measured by
two-site enzyme immunoassay. Each value is the mean, while the vertical bar with
small horizontal bars indicates the standard deviation.
Fig. 3. Effect of each treatment on epidermal hypertrophy in NC/Nga mice. Female NC/Ng
FTY720 ointment, 100 mg/affected area, n ¼ 8), (2) tacrolimus (tacrolimus hydrate ointmen
affected area, n ¼ 8), or (4) ointment base (hydrophilic petrolatum, 100 mg/affected area, n
mice with no symptoms (n ¼ 4) were stained with hematoxylin and eosin. Epidermal thick
mean, while the vertical bar with small horizontal bars indicates the standard deviation.
ManneWhitney U test. NS, not signiﬁcant. (b) Representative pictures, illustrating different
T. Tsuji et al. / Allergology International 65 (2016) 172e179174Rinderon-V ointment) was purchased from Shionogi Pharmaceu-
tical Co., Ltd., Osaka, Japan. Tacrolimus hydrate ointment (0.1%
Protopic ointment) was purchased from Astellas Pharma Inc.,
Tokyo, Japan.
Induction of AD
Ten mg of freeze-dried mite Dermatophagoides farinae crude
extract (Df) (Mite Extract-Df; Cosmo Bio Co., Ltd., Tokyo, Japan) was
mixed with 4 g hydrophilic petrolatum (Maruishi Pharmaceutical
Co., Ltd., Osaka, Japan) at a concentration of 2.5 mg Df/1 g hydro-
philic petrolatum (hereafter referred to as Df ointment). The mice
were anesthetized with chloral hydrate, and the hair on their back
was shaved with an electric shaver. AD was induced by topical
application of 100 mg Df ointment on the shaved dorsal skin. Bar-
rier disruption was achieved using 150 mL 4% sodium dodecyl sul-
fate treatment on the shaved dorsal skin three hours prior to Df
ointment application. These procedures were repeated twice per
week for 4 weeks.22
AD severity
AD severity was evaluated daily. Development of (1) erythema/
hemorrhage, (2) scarring/dryness, (3) edema, and (4) excoriation/
erosionwas scored as 0 (none), 1 (mild), 2 (moderate), or 3 (severe).
The AD score was deﬁned as the sum of the individual scores.22a mice with severe skin lesions were treated for two weeks with (1) FTY720 (0.001%
t, 100 mg/affected area, n ¼ 8), (3) betamethasone (betamethasone ointment, 100 mg/
¼ 8) six times per week. (a) Skin sections from each mouse and age-matched NC/Nga
ness was measured under a microscope at a magniﬁcation of 200. Each value is the
The signiﬁcance of the difference in epidermal hypertrophy was examined using the
extents of epidermal hypertrophy at the end of the observation period in each group.
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This study was composed of two separate experiments. Female
NC/Nga mice with skin lesions were divided into four groups: (1)
FTY720 (0.001% FTY720 ointment, 100 mg/affected area, n ¼ 8), (2)
tacrolimus (tacrolimus hydrate ointment, 100 mg/affected area,
n ¼ 8), (3) betamethasone (betamethasone ointment, 100 mg/
affected area, n ¼ 8), and (4) ointment base (hydrophilic petro-
latum,100 mg/affected area, n¼ 8), all of which received treatment
six times per week. Meanwhile, age-matched NC/Nga mice (n ¼ 4),
which did not undergo Df ointment application, were used as
controls. To ensure that the amount of FTY720 in the ointment did
not cause any decrease in the number of CD3þ T cells in peripheral
blood, the number of CD3þ T cells was measured on days 0, 7, and
14 by ﬂow cytometry. Treatment was continued for two weeks.
These treatment regimens were similar to those reported by
Yamamoto et al.22 Clinical symptoms of AD were checked every day
and scored as described above.Measurement of serum IgE level
Measurement of serum IgE level was based on our previous
study.10 On days 7, 0, 7, and 14 after elicitation, peripheral blood
samples were collected, and the levels of serum IgE antibody were
measured bymeans of a two-site enzyme immunoassay kit (Mouse
IgE ELISA MAX Standard Set; BioLegend, Inc., San Diego, CA, USA).Fig. 4. Effect of each treatment on the number of mast cells in NC/Nga mice. Female NC/N
FTY720 ointment, 100 mg/affected area, n ¼ 8), (2) tacrolimus (tacrolimus hydrate ointmen
affected area, n ¼ 8), or (4) ointment base (hydrophilic petrolatum, 100 mg/affected area, n
mice with no symptoms (n ¼ 4) were stained with 0.05% toluidine blue solution. Inﬁltratio
of 200. Each value is the mean, while the vertical bar with small horizontal bars indicates
examined using the ManneWhitney U test. NS, not signiﬁcant. (b) Representative pictures,Histochemical staining
AD-associated epidermal hypertrophy and the number of inﬁl-
trated mast cells were assessed according to methods used in our
previous study.10 After the treatment period, lesional or nonlesional
dorsal skinwas removed, ﬁxed with 10% buffered formalin solution
(Wako Pure Chemical Industries, Ltd., Osaka, Japan), embedded in
parafﬁn according to the conventional method, and cut into 3- to 4-
mm sections. The sections were stained with hematoxylin and eosin
(Mayer's Hematoxylin Solution; Wako Pure Chemical Industries,
Ltd.) and sodium tetrabromoﬂuorescein (Wako Pure Chemical In-
dustries, Ltd.), and with toluidine blue (0.05% Toluidine Blue Solu-
tion; Muto Pure Chemicals Co., Ltd., Tokyo, Japan). The number of
mast cells in the dermis was counted under the microscope and
quantiﬁed using imaging software (Image J).Immunostaining for CD3þ T cells
The number of inﬁltrated CD3þ T cells was assessed according
to methods used in our previous study.10 Parafﬁn embedded
tissue was cut into 3- to 4-mm sections. The sections were stained
for CD3 using polyclonal goat anti-mouse CD3 antibody (Santa
Cruz Biotechnology, Inc., CA, USA) and peroxidase-conjugated
polyclonal anti-goat IgG antibody (Medical and Biological Labo-
ratories Co., Ltd., Nagoya, Japan); visualization was carried out
with diaminobenzidine. The number of CD3þ T cells in thega mice with severe skin lesions were treated for two weeks with (1) FTY720 (0.001%
t, 100 mg/affected area, n ¼ 8), (3) betamethasone (betamethasone ointment, 100 mg/
¼ 8) six times per week. (a) Skin sections from each mouse and age-matched NC/Nga
n of mast cells into the dermis was measured under a microscope at a magniﬁcation
the standard deviation. The signiﬁcance of the difference in mast cell inﬁltration was
illustrating inﬁltrating mast cells at the end of the observation period in each group.
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Image J.
Measurement of transepidermal water loss
On days 7, 0, 7, and 14 after elicitation, transepidermal water
loss (TEWL) of the shaved dorsal skin was measured by means of a
TEWA meter (TM 120; Courage and Khazaka, K€oln, Germany).
Resulting data were analyzed by a microprocessor, and were
expressed in g/m2/h.
Immunostaining for ﬁlaggrin
After the treatment period, lesional or nonlesional dorsal skin
was removed, ﬁxed with 4% buffered paraformaldehyde solution
(Wako Pure Chemical Industries, Ltd.), embedded in OCTcompound
(Sakura Finetek Japan Co., Ltd., Tokyo, Japan), and cut into 10-mm
frozen sections with a cryostat. The sections were stained for ﬁlag-
grin using a polyclonal rabbit anti-ﬁlaggrin IgG antibody (Covance
Inc., Princeton, NJ, USA). Then, the sections were incubated with
Alexa Fluor 488-conjugated goat anti-rabbit IgG (HþL) antibody
(Life Technologies, Carlsbad, CA, USA) for 1 h at 20 C. Finally, the cell
nuclei were stained with Hoechst 33342 (Lonza Group Ltd., Wal-
kersville, MD, USA) for 1 min at room temperature and examined
under a ﬂuorescence microscope; the ﬂuorescence intensity of
ﬁlaggrin was then measured using imaging software (Image J).
Statistical analysis
The signiﬁcance of differences in AD score, epidermal hyper-
trophy, serum IgE level, and TEWL were evaluated using theFig. 5. Effect of each treatment on the number of CD3þ T cells in NC/Nga mice. Female
NC/Nga mice with severe skin lesions were treated for two weeks with (1) FTY720
(0.001% FTY720 ointment, 100 mg/affected area, n ¼ 8), (2) tacrolimus (tacrolimus
hydrate ointment, 100 mg/affected area, n ¼ 8), (3) betamethasone (betamethasone
ointment, 100 mg/affected area, n ¼ 8), or (4) ointment base (hydrophilic petrolatum,
100 mg/affected area, n ¼ 8) six times per week. Skin sections from each mouse and
age-matched NC/Nga mice with no symptoms (n ¼ 4) were stained for CD3 using
polyclonal goat anti-mouse CD3 antibody and peroxidase-conjugated polyclonal anti-
goat IgG antibody. The number of CD3þ T cells in the dermis was counted under the
microscope and quantiﬁed using Image J. Each value is the mean, while the vertical bar
with small horizontal bars indicates the standard deviation. The signiﬁcance of the
difference in mast cell inﬁltration was evaluated using the ManneWhitney U test. NS,
not signiﬁcant.ManneWhitney U test or the paired Student's t test, where
appropriate. P < 0.05 was considered statistically signiﬁcant.
Results
Therapeutic effect
In the betamethasone group, no marked improvement in AD
was observed; the mean AD scores before and after treatment were
6.3 ± 1.2 and 4.1 ± 1.2, respectively (Fig. 1). These results indicate
that the severe skin lesions in this mouse model were indeed ste-
roid resistant. In the tacrolimus group, the therapeutic efﬁcacy was
limited, and improvement was not signiﬁcant compared with the
ointment base group; the mean AD scores before and after treat-
ment were 6.0 ± 1.3 and 2.8 ± 1.0, respectively (Fig. 1). In the
FTY720 group, improvement was signiﬁcant compared with the
betamethasone and ointment base groups (P < 0.05); the mean AD
scores before and after treatment were 5.9 ± 1.0 and 1.8 ± 1.3,
respectively (Fig. 1). The results of this study were similar to those
of our previous study investigating oral therapy.11
Serum IgE level
As shown in Figure 2, IgE concentration was elevated after
topical application of Df ointment on the shaved dorsal skin. No
decrease in IgE concentration was observed in any of the four
groups, and there was no signiﬁcant difference in IgE concentration
among the groups (Fig. 2).
Histochemical study
AD-associated epidermal hypertrophy improved signiﬁcantly in
the FTY720 group but not in the betamethasone or tacrolimusFig. 6. Effect of each treatment on transepidermalwater loss inNC/Ngamice. FemaleNC/
Nga mice with severe skin lesions were treated for two weeks with (1) FTY720 (0.001%
FTY720 ointment, 100 mg/affected area, n ¼ 8,C), (2) tacrolimus (tacrolimus hydrate
ointment,100mg/affected area, n¼ 8,>), (3) betamethasone (betamethasoneointment,
100 mg/affected area, n ¼ 8,,), or (4) ointment base (hydrophilic petrolatum, 100 mg/
affected area, n ¼ 8,△) six times per week. B ¼ age-matched NC/Nga mice with no
symptoms (n ¼ 4). The transepidermal water loss (TEWL) of each mouse was measured.
Each symbol indicates an individual mouse. The signiﬁcance of the difference in TEWL of
each treatmentperiodwasexaminedusing thepairedStudent's t test,while thatbetween
treatment groups was examined using the MannWhitney U test. NS, not signiﬁcant.
T. Tsuji et al. / Allergology International 65 (2016) 172e179 177groups (Fig. 3). As for mast cell inﬁltration into the dermis, the
number of mast cells was signiﬁcantly lower in the FTY720 group
than in the ointment base group. In addition, the number of mast
cells was comparable in the FTY720 group and in mice without
symptoms. The tacrolimus and betamethasone groups, however,
showed no difference compared with the ointment base group
(Fig. 4). There was no signiﬁcant difference in mast cell degranu-
lation among groups (data not shown). With regard to inﬂamma-
tory cell inﬁltration into the dermis, the numbers of CD3þ T cells in
the FTY720, tacrolimus, and betamethasone groups were signiﬁ-
cantly decreased compared with those in the ointment base group
(Fig. 5). This result in the betamethasone group is similar to that of
our previous study.11 However, the number of inﬁltrating CD3þ T
cells with oral FTY720 therapy was not decreased, but it was
signiﬁcantly decreased in the FTY720 ointment group compared
with that in the ointment base group.
Recuperative effect on skin barrier function
TEWL in the FTY720 and tacrolimus groups decreased signiﬁ-
cantly from before treatment to after treatment (FTY720 group:
60 ± 12 g/m2/h/ 26 ± 14 g/m2/h; tacrolimus group: 63 ± 10 g/m2/
h/ 45 ± 14 g/m2/h) (P < 0.05). On day 14 after the ﬁrst treatment,
TEWL in the FTY720 group was signiﬁcantly decreased compared
with that in the betamethasone (59 ± 30 g/m2/h) and ointmentFig. 7. Effect of each treatment on epidermal barrier function in NC/Nga mice. Female NC/N
FTY720 ointment, 100 mg/affected area, n ¼ 8), (2) tacrolimus (tacrolimus hydrate ointmen
affected area, n ¼ 8), or (4) ointment base (hydrophilic petrolatum, 100 mg/affected area, n
mice with no symptoms (n ¼ 4) were stained for ﬁlaggrin using polyclonal rabbit anti-ﬁlag
goat anti-rabbit IgG (HþL) antibody. Finally, the sections were examined under a ﬂuoresc
imaging software (Image J). Each value is the mean, while the vertical bar with small horizon
of expression of ﬁlaggrin was examined using the ManneWhitney U test. NS, not signiﬁca
shown.base groups (48 ± 14 g/m2/h). TEWL after treatment was similar to
that observed in age-matched NC/Nga mice with no symptoms
(28 ± 23 g/m2/h). In the other groups, no signiﬁcant decrease in
TEWL was observed (Fig. 6). Furthermore, the intensity of ﬁlaggrin
expression in the FTY720 group was signiﬁcantly greater than that
in the betamethasone and ointment base groups, andwas similar to
age-matched NC/Nga mice with no symptoms (Fig. 7).
Discussion
The incidence of AD has been increasing in recent years
throughout the world, especially in children.23 As for steroid-
resistant AD, Leung et al.24 reported that Staphylococcus aureus
infection induces resistance to corticosteroids, while Li et al.25 re-
ported that glucocorticoid receptor-b controls expression of histone
deacetylase 2 by inhibiting glucocorticoid response; this inhibition
is the cause of steroid insensitivity. With regard to steroid-resistant
AD, Sears et al.26 reported that 69% of patients with AD treated with
hydrocortisone buteprate showed excellent or good results. In
other words, the remaining 31% of patients were considered to have
steroid-resistant AD. In another respect, tacrolimus hydrate oint-
ment is particularly useful for treating skin lesions on the face or
neck, but 1.9% of patients develop opportunistic infection (e.g.,
eczema herpeticum).27 Furthermore, in another study, NC/Nga
mice treated with tacrolimus hydrate ointment did not achievega mice with severe skin lesions were treated for two weeks with (1) FTY720 (0.001%
t, 100 mg/affected area, n ¼ 8), (3) betamethasone (betamethasone ointment, 100 mg/
¼ 8) six times per week. (a) Skin sections from each mouse and age-matched NC/Nga
grin IgG antibody. Then, the sections were incubated with Alexa Fluor 488-conjugated
ence microscope at a magniﬁcation of 200. Staining intensity was measured using
tal bars indicates the standard deviation. The signiﬁcance of the difference in intensity
nt. (b) Representative pictures at the end of the observation period in each group are
T. Tsuji et al. / Allergology International 65 (2016) 172e179178complete remission.28 Thus, it seems necessary to develop a more
effective regimen to treat steroid-resistant AD.
We previously reported that oral administration of FTY720
completely prevented spontaneous development of AD in NC/Nga
mice,9 and FTY720 in combination with betamethasone ointment
provided dramatic relief of spontaneous10 and mite-induced AD.11
In this study, we examined the local therapeutic efﬁcacy of
FTY720 ointment for established steroid-resistant AD using an NC/
Nga mouse model.
In this study, 0.001% FTY720 ointment had no effect on the
number of CD3þ T cells in peripheral blood; on days 0, 7, and 14, the
numbers of CD3þ Tcells in the FTY720 groupwere 517 ± 97 cells/mL,
503 ± 137 cells/mL, and 574 ± 200 cells/mL, respectively. The number
of mast cells inﬁltrating into the dermis was signiﬁcantly lower in
the FTY720 group compared with the ointment base group. Addi-
tionally, application of FTY720 ointment was not related to IgE
production in mite-induced AD. These results are well matched
with those of our previous study.10 As described in our previous
paper,10 FTY720 binds to S1PRs, except S1P2. Mast cells express two
of the ﬁve S1PRs (S1P1 and S1P2). In mast cells, S1P1 regulates
migration toward antigens and sites of inﬂammation.29 S1P2 is
important for proper mast cell degranulation induced by antigen-
mediated cross-linking of Fc 3RI.29 In addition, Kleinjan et al.30
indicated the possibility that FTY720 might induce apoptosis of
mast cells, potentially acting preferentially on newly recruitedmast
cells, whereas resident mast cells are unaffected. Furthermore, the
number of CD3þ T cells inﬁltrating into the dermis was signiﬁcantly
lower in the FTY720 group than in the ointment base group, and
was similar to the number in age-matched NC/Nga mice with no
symptoms. Kleinjan et al.30 also indicated that topical treatment
with FTY720 impaired T cell proliferation and Th2 cell differentia-
tion. In future studies, the mechanism underlying the decrease in
CD3þ T cells should be further investigated. In either case, these
results suggest that treatment with FTY720 ointment is associated
with a low risk of infection.
In the present study, we demonstrated that TEWL improved
signiﬁcantly after FTY720 treatment, and was a similar level as that
in age-matched NC/Nga mice with no symptoms. Furthermore, the
intensity of ﬁlaggrin expression in the FTY720 group was signiﬁ-
cantly increased compared with that in the betamethasone and
ointment base groups. The Th2 cytokines (IL-4, IL-13, and IL-31) and
the Th22 cytokine IL-22 reduce ﬁlaggrin expression.1 Thymic
stromal lymphopoietin (TSLP) enhances dendritic cell driven Th2
cell differentiation, and expression of TSLP in the skin is deeply
committed to AD.31 Thus, the next step will be to establish in detail
the mechanism though which the expression of TSLP in the skin is
suppressed by FTY720 ointment. Meanwhile, Scott et al.32 reported
that ﬁlaggrin proteolysis occurs on exposure to a low-humidity
environment and might be inhibited by high humidity. Therefore,
repair of the TJ barrier would restore a high-humidity environment
and possibly inhibit ﬁlaggrin proteolysis. In fact, in this study,
ﬁlaggrin expression in the FTY720 group was similar to that in age-
matched NC/Nga mice with no symptoms.
In conclusion, the results of this study indicate that FTY720
ointment is a promising candidate for treatment of steroid-
resistant human AD.Acknowledgments
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